N

Nicholas P. Restifo

Lyell Immunopharma (United States)

Publishes on Immunotherapy and Immune Responses, CAR-T cell therapy research, Immune Cell Function and Interaction. 675 papers and 97.1k citations.

PubIndex Score98Top 2%How it's scored

🌟#4 Current Senior Leader in CAR-T cell therapy research 🌟#7 Current Senior Leader in Immunotherapy and Immune Responses 🌟#9 Current Senior Leader in vaccines and immunoinformatics approaches

675Publications

97.1kTotal Citations

#4in CAR-T cell therapy research

First publication: 1985First senior author: 1994

Immunotherapy and Immune Responses CAR-T cell therapy research Immune Cell Function and Interaction Cancer Immunotherapy and Biomarkers T-cell and B-cell Immunology

Top publicationsby citations

Identification of essential genes for cancer immunotherapy

Shashank J. Patel, Nicholas P. Restifo|Nature|2017

Cited by 890

IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy

Christian S. Hinrichs, Nicholas P. Restifo|Blood|2008

Cited by 459

Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?

Pawel Muranski, Nicholas P. Restifo|Nature Clinical Practice Oncology|2006

Cited by 348

BACH2 regulates CD8+ T cell differentiation by controlling access of AP-1 factors to enhancers

Rahul Roychoudhuri, Nicholas P. Restifo|Nature Immunology|2016

Cited by 329

Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy

Christopher A. Klebanoff, Nicholas P. Restifo|JCI Insight|2017

Cited by 221